Pharmacoeconomic issues in head and neck oncology

Jonas A. De Souza, Gilberto De Lima Lopes, Ezra E W Cohen

Research output: Contribution to journalArticle

Abstract

PURPOSE OF REVIEW: Despite medical advances, the global incidence, morbidity and mortality associated with head and neck cancer remain high. Pharmacoeconomic analyses of chemotherapeutic options commonly used by head and neck oncologists are reviewed in context with current clinical practice. RECENT FINDINGS: From the British health system perspective, cetuximab with radiotherapy in locally advanced head and neck was found to be cost-effective compared to single modality radiotherapy in patients with a good performance status, and in whom platinum agents are contraindicated. Induction chemotherapy with the three-drug regimen docetaxel, cisplatin and 5-fluorouracil is considered cost-effective when compared to the doublet cisplatin-5-fluorouracil from the British and Italian perspectives. However, it is unclear whether induction chemotherapy per se is effective when compared to chemoradiotherapy. Cetuximab with chemotherapy is not recommended from a British health perspective for patients with metastatic/recurrent disease, whereas it is the preferred regimen in commonly used guidelines in the US, where economic evaluations are not incorporated in the drug approval process. SUMMARY: The critical assessment and utilization of pharmacoeconomic evaluations, always in context with current clinical practice, should be further performed and promoted in head and neck oncology.

Original languageEnglish (US)
Pages (from-to)213-217
Number of pages5
JournalCurrent Opinion in Oncology
Volume25
Issue number3
DOIs
StatePublished - May 2013

Fingerprint

Pharmaceutical Economics
Induction Chemotherapy
Neck
Head
docetaxel
Fluorouracil
Cisplatin
Radiotherapy
Drug Approval
Costs and Cost Analysis
Health
Chemoradiotherapy
Head and Neck Neoplasms
Platinum
Cost-Benefit Analysis
Guidelines
Morbidity
Drug Therapy
Mortality
Incidence

Keywords

  • cost of cancer care
  • head and neck cancer
  • pharmacoeconomics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

De Souza, J. A., Lopes, G. D. L., & Cohen, E. E. W. (2013). Pharmacoeconomic issues in head and neck oncology. Current Opinion in Oncology, 25(3), 213-217. https://doi.org/10.1097/CCO.0b013e32835ff422

Pharmacoeconomic issues in head and neck oncology. / De Souza, Jonas A.; Lopes, Gilberto De Lima; Cohen, Ezra E W.

In: Current Opinion in Oncology, Vol. 25, No. 3, 05.2013, p. 213-217.

Research output: Contribution to journalArticle

De Souza, Jonas A. ; Lopes, Gilberto De Lima ; Cohen, Ezra E W. / Pharmacoeconomic issues in head and neck oncology. In: Current Opinion in Oncology. 2013 ; Vol. 25, No. 3. pp. 213-217.
@article{c9b14e3869464f13ab3b7f83992cd473,
title = "Pharmacoeconomic issues in head and neck oncology",
abstract = "PURPOSE OF REVIEW: Despite medical advances, the global incidence, morbidity and mortality associated with head and neck cancer remain high. Pharmacoeconomic analyses of chemotherapeutic options commonly used by head and neck oncologists are reviewed in context with current clinical practice. RECENT FINDINGS: From the British health system perspective, cetuximab with radiotherapy in locally advanced head and neck was found to be cost-effective compared to single modality radiotherapy in patients with a good performance status, and in whom platinum agents are contraindicated. Induction chemotherapy with the three-drug regimen docetaxel, cisplatin and 5-fluorouracil is considered cost-effective when compared to the doublet cisplatin-5-fluorouracil from the British and Italian perspectives. However, it is unclear whether induction chemotherapy per se is effective when compared to chemoradiotherapy. Cetuximab with chemotherapy is not recommended from a British health perspective for patients with metastatic/recurrent disease, whereas it is the preferred regimen in commonly used guidelines in the US, where economic evaluations are not incorporated in the drug approval process. SUMMARY: The critical assessment and utilization of pharmacoeconomic evaluations, always in context with current clinical practice, should be further performed and promoted in head and neck oncology.",
keywords = "cost of cancer care, head and neck cancer, pharmacoeconomics",
author = "{De Souza}, {Jonas A.} and Lopes, {Gilberto De Lima} and Cohen, {Ezra E W}",
year = "2013",
month = "5",
doi = "10.1097/CCO.0b013e32835ff422",
language = "English (US)",
volume = "25",
pages = "213--217",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Pharmacoeconomic issues in head and neck oncology

AU - De Souza, Jonas A.

AU - Lopes, Gilberto De Lima

AU - Cohen, Ezra E W

PY - 2013/5

Y1 - 2013/5

N2 - PURPOSE OF REVIEW: Despite medical advances, the global incidence, morbidity and mortality associated with head and neck cancer remain high. Pharmacoeconomic analyses of chemotherapeutic options commonly used by head and neck oncologists are reviewed in context with current clinical practice. RECENT FINDINGS: From the British health system perspective, cetuximab with radiotherapy in locally advanced head and neck was found to be cost-effective compared to single modality radiotherapy in patients with a good performance status, and in whom platinum agents are contraindicated. Induction chemotherapy with the three-drug regimen docetaxel, cisplatin and 5-fluorouracil is considered cost-effective when compared to the doublet cisplatin-5-fluorouracil from the British and Italian perspectives. However, it is unclear whether induction chemotherapy per se is effective when compared to chemoradiotherapy. Cetuximab with chemotherapy is not recommended from a British health perspective for patients with metastatic/recurrent disease, whereas it is the preferred regimen in commonly used guidelines in the US, where economic evaluations are not incorporated in the drug approval process. SUMMARY: The critical assessment and utilization of pharmacoeconomic evaluations, always in context with current clinical practice, should be further performed and promoted in head and neck oncology.

AB - PURPOSE OF REVIEW: Despite medical advances, the global incidence, morbidity and mortality associated with head and neck cancer remain high. Pharmacoeconomic analyses of chemotherapeutic options commonly used by head and neck oncologists are reviewed in context with current clinical practice. RECENT FINDINGS: From the British health system perspective, cetuximab with radiotherapy in locally advanced head and neck was found to be cost-effective compared to single modality radiotherapy in patients with a good performance status, and in whom platinum agents are contraindicated. Induction chemotherapy with the three-drug regimen docetaxel, cisplatin and 5-fluorouracil is considered cost-effective when compared to the doublet cisplatin-5-fluorouracil from the British and Italian perspectives. However, it is unclear whether induction chemotherapy per se is effective when compared to chemoradiotherapy. Cetuximab with chemotherapy is not recommended from a British health perspective for patients with metastatic/recurrent disease, whereas it is the preferred regimen in commonly used guidelines in the US, where economic evaluations are not incorporated in the drug approval process. SUMMARY: The critical assessment and utilization of pharmacoeconomic evaluations, always in context with current clinical practice, should be further performed and promoted in head and neck oncology.

KW - cost of cancer care

KW - head and neck cancer

KW - pharmacoeconomics

UR - http://www.scopus.com/inward/record.url?scp=84876205429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876205429&partnerID=8YFLogxK

U2 - 10.1097/CCO.0b013e32835ff422

DO - 10.1097/CCO.0b013e32835ff422

M3 - Article

C2 - 23508082

AN - SCOPUS:84876205429

VL - 25

SP - 213

EP - 217

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 3

ER -